Çetinkaya Semra, Eren Erdal, Erdoğan Furkan, Darendeliler Feyza
University of Health Sciences Türkiye, Ankara Dr. Sami Ulus Obstetrics and Gynecology, Child Health and Diseases Training and Research Hospital, Clinic of Child Health and Diseases, Ankara, Türkiye
Bursa Uludağ University Faculty of Medicine, Department of Child Health and Diseases, Bursa, Türkiye
J Clin Res Pediatr Endocrinol. 2025 Mar 19;17(1):1-8. doi: 10.4274/jcrpe.galenos.2024.2023-11-8. Epub 2024 Mar 15.
Recombinant growth hormone (GH) is administered as daily subcutaneous injections. Daily treatment can be challenging for children/adolescents, as well as for parents and/or caregivers, such as legal representatives or guardians of children in institutional care. Challenges associated with daily treatment may result in missing several doses but non-adherence with treatment leads to inadequate growth response. As an inadequate growth response does not meet criteria for continuing treatment, payers (commercial or public) may decide to end reimbursement. Novel long-acting GH (LAGH) formulations with extended half-life may be administered less frequently and aim to improve patient convenience and consequently to improve adherence and responses to treatment. LAGH formulations can restore growth velocity and body composition as effectively as daily treatment, without unexpected adverse effects, as reported in randomized clinical trials.
重组生长激素（GH）通过每日皮下注射给药。每日治疗对于儿童/青少年以及父母和/或护理人员（如机构照料中儿童的法定代表或监护人）来说可能具有挑战性。与每日治疗相关的挑战可能导致错过几剂，但不坚持治疗会导致生长反应不足。由于生长反应不足不符合继续治疗的标准，支付方（商业或公共）可能会决定终止报销。半衰期延长的新型长效生长激素（LAGH）制剂给药频率可能较低，旨在提高患者便利性，从而改善依从性和治疗反应。随机临床试验报告显示，LAGH制剂恢复生长速度和身体成分的效果与每日治疗一样有效，且无意外不良影响。
